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mitral valve disease.
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BACKGROUND The REALISM study, the largest US-based study of the
MitraClip Device, is a continued access registry designed for long-term
data collection on the use of MitraClip Device in a “real world” setting.
Retrospective analyses are being performed to determine the proce-
dural learning curve related to the MitraClip procedure.
METHODS A total of 628 high risk and 271 non-high risk patients, with
symptomatic chronic moderate-to-severe (3þ) or severe (4þ) mitral
regurgitation (MR), were enrolled at 38 centers with varying degrees
of experience. Learning curve effects on procedural, safety, and efﬁ-
cacy parameters are of particular interest will be investigated.
RESULTS Initial analyses indicate signiﬁcant reduction in procedure
and device time as sites gain experience with the MitraClip device.
Following initial experience, reduction in procedure, device, and
ﬂuoroscopy time was observed, with continuing trend of further
gradual reduction in time. The effect of learning curve on safety and
efﬁcacy is being analyzed.
CONCLUSIONS Initial analysis demonstrates reduction in procedure
time is achieved as each site gains experience. Further analysis will
determine any changes in efﬁcacy and/or safety outcomes associated
with further experience in this large study cohort.
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BACKGROUND Mean mitral gradient (MMG) increases after percuta-
neous edge-to-edge repair of mitral regurgitation (MR). Near complete
reduction of MR has been associated with improved outcomes but
may result in an elevated MMG. However, it is not known whether an
elevated post-procedural MMG is associated with all-cause mortality.
METHODS Patients (pts) who underwent percutaneous repair of MR
between April 2009 and May 2014 with the MitraClip device (Abbott
Vascular, Santa Clara, CA) were included. An elevated gradient was
deﬁned as a MMG 5 mmHg on transthoracic echocardiogram prior to
discharge. Survival was compared between pts with and without an
elevated post-procedural MMG by Log Rank test. Univariate Cox
regression analysis of all-cause mortality was performed for the
predictor variables of post-procedural MMG and change in MMG.
Multivariate logistic regression analysis of predictors for an elevated
post-procedural MMG was performed for normal ejection
fraction 60%, reduction of MR  mild-or-moderate, number of clips
placed, and age.
RESULTS 174 pts were included in the analysis. Mean age at
percutaneous repair was 76.9  12.6 yrs and 40.8% were females.
Post-procedural MMG ranged from 1 to 10 mmHg. An elevated post-
procedural MMG 5 mmHg occurred in 52/174 (29.9%) of pts with an
average MMG of 5.9  1.2 mmHg in this group. MMG was signiﬁcantly
lower in the remaining pts (2.7  0.9 mmHg) p<0.001. Baseline MR
was moderate-to-severe in 36/174 (20.7%) of pts and severe in 138/174
(79.3%) of pts and not different between the groups (p¼1.000).
Number of clips used was 1.5  0.5 (median 2) and not different be-
tween the groups (p¼0.144). Procedural success of reducing MR by 2
or more grades (95.4% of pts) or to less than or equal to mild-or-
moderate (82.8% of pts) was not different between groups p¼0.242
and p¼0.665, respectively. Pts with an elevated post-procedural MMG
had a higher increase in MMG 3.6  1.5 vs. 0.9  1.0 mmHg (p<0.001)
after clipping. Pts with an elevated post-procedural MMG had
improved survival (Log rank p¼0.036). In univariate Cox regression
analysis both post-procedural MMG and change in MMG were asso-
ciated with decreased all-cause mortality hazard ratio 0.839 (95% CI
0.721 – 0.977) p¼0.024 and 0.830 (95% CI 0.711 – 0.969) p¼0.019,
respectively. On multivariate logistic regression analysis pts with
normal ejection fraction 60% had an odds ratio of 2.241 (95% CI 1.125
– 4.461) p¼0.022 for developing an elevated post-procedural MMG.
Reduction of MR to  mild-or-moderate, number of clips, and age
were not signiﬁcantly associated with an elevated post-procedural
MMG.
CONCLUSIONS Moderate elevation of post-procedural MMG is not
associated with increased mortality and may be the expression of
improved hemodynamics. An increase of MMG 3 mmHg to a post-
procedural MMG of 5-10 mmHg might be expected for optimal
outcomes.
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BACKGROUND Right ventricular function is an important determi-
nant of clinical symptoms, exercise capacity, and survival in patients
with Mitral Stenosis. The aim of this study is to evaluate immediate
and mid-term impact of successful percutaneous transvenous mitral
commissurotomy (PTMC) on systolic right ventricular function.
METHODS Twelve patients with severe symptomatic mitral stenosis
who underwent PTMC were included, all patients were subjected to
transthoracic echocardiography assessment of severity of mitral ste-
nosis and right ventricular systolic function before and 24h post-
PTMC then at one and three months.
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patients (16,7%) had previous PTMC, quarter of patients were in atrial
ﬁbrillation, all patients were symptomatic. Mitral valve area increased
from 1.05þ/-0.26 cm2 to 2.02þ/-0.45 cm2 (p<0.0001). Mean gradient
decreased from 13.52þ/-5.09 mmHg to 5.38 þ/- 3.15 mmHg (p<0.0001).
There was a signiﬁcant decrease in systolic pulmonary artery pressure
from 38.13þ/-7,55 mmHg to 28,25þ/-4.65mmHg (p¼0.006). Pulmonary
resistance measured by echocardiography using Tricuspid regurgita-
tion Vmax / Tricuspid VTI ratio dropped from 0.140þ/-0.017 to
0.116þ/- 0.015 (p¼0.023). Tricuspid annular point systolic excursion
(TAPSE) increased from 21.58þ/-3.08mm to 24.25þ/-4.80mm
(p¼0.029) then to 24.10þ/-5.28mm (p¼0.091) and to 24.10þ/-5.28mm
(p ¼0.091). Systolic velocity (S’) at lateral tricuspid annulus increased
from 12.80þ/-3.76cm to 14.90þ/-3.98cm (p¼0.004) and to 14.80þ/-
3.79cm (p¼0.015) then to 15.60þ/-3.92cm (p¼0.001). Tei index
decreased from 0.359þ/-0.222 to 0.207þ/-0.095 (p¼0.026) and to
0.203þ/-0.089 (p¼0.024) then to 0.201þ/-0.086 (p¼0.014). Myocar-
dial acceleration during isovolumic contraction (IVA) increased from
0.410þ/-0.106 m/s2 (p¼0.027) to 0.568þ/-0.256 m/s2 and to 0.570þ/-
0.218 m/s2 (p¼0.010) then to 0.615þ/-0.231 m/s2 (p¼0.003) respec-
tively at baseline, 24h, one month and three months after PTMC.
There was no signiﬁcant fraction area change and dp/dt ratio of the
right ventricle immediately and at mid term after PTMC.
CONCLUSIONS We suggest that there is an immediate improvement
of right ventricular systolic function after PTMC that is maintained at
mid term follow-up. Also the fact that this tendency was conﬁrmed by
using echocardiographic parameters those are loading dependent
such TAPSE and others less loading dependent such IVA suggest that
those improvements could be independent from loading conditions.
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BACKGROUND Right ventricular dysfunction (RVdisf) is predictor of
poor outcome in patients with heart failure and valvular disease. The
aim of this study was to evaluate the impact and the evolution of
RVdisf in patients with moderate-severe functional mitral regurgita-
tion (FMR) after MitraClip.
METHODS From October 2008 to July 2014, 60 consecutive high
surgical risk patients were treated and stratiﬁed into two groups:
RVdysf-group (TAPSE <16 mm and/or S’TDS <10 cm/sec, 21 patients)
and No-RVdysf-group (38 patients).
RESULTS The overall mean age was 738 (83% male). Ischemic FMR
etiology was present in 67%. Mean LVEF was 3010. Between the two
groups the only signiﬁcant differences was in presence of stroke, ICD
and use of aldosterone-antagonist higher in RVdysf group. Acute
procedural success was achieved in 90%. At 6-month echocardio-
graphic follow-up signiﬁcant improvement of RV function was
observed in all patients and was driven by only the results of patients
with RVdysf (TAPSE 153.0 vs. 194.5, p¼0.007; S’ TDI 71.2 vs.
112.8, p<0.0001; baseline vs. 6-month, respectively). Overall mean
follow-up was 565310 days. Mean improvement in 6-MWT was 116 m
(signiﬁcant in both groups).
CONCLUSIONS This observational study shows that patients with
RVdysf and FMR have signiﬁcant improvement of RV function after
MitraClip procedure. The presence of RVdysf was not predictor of
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BACKGROUND The risk of surgical mitral valve replacement in pa-
tients with severe mitral annular calciﬁcation (MAC) is very high due
to comorbidities and technical challenges related to calcium burden,
precluding surgery in many patients. There are few isolated reports of
successful transcatheter mitral valve replacement (TMVR) with
balloon expandable valves in this patient population. We report the
ﬁrst large analysis from a global registry of TMVR in MAC.
METHODS 44 patients in 17 centers from 8 different countries un-
derwent TMVR with the compassionate use of SAPIEN (Edwards
Lifesciences, Irvine, CA) valves between September of 2012 and April
of 2015.
RESULTS The mean age was 74 years (range 39-94), 71% were fe-
males, mean STS score 14.6% (range 1-29%). Most patients (91%) had
mitral stenosis and 9% mitral regurgitation. The average mean
gradient was 12 mmHg, mean area 1.04 cm2. The SAPIEN valve was
used in 11%, SAPIEN XT in 71% and SAPIEN 3 in 18% (23mm¼4.5%,
26 mm¼43.5%, 29mm¼52%). The delivery approach was transatrial in
11%, transapical in 41%, and transeptal in 48%. The valve was
implanted without embolization in 41 (93%) patients, 6 (14%) required
a second valve-in-valve (migration¼2, regurgitation¼4), and 5 (11%)
had left ventricular tract obstruction (LVOTO) with hemodynamic
